Answers are grounded in this paper and cite their sources.
Leveraging molecular dynamics simulations enhances drug design for psychedelics, promising safer clinical candidates.
MD simulations are transforming psychedelic drug discovery from serendipity to precision design. While immediate impact lies in accelerating lead optimization through in silico screening of biased signaling and multimer-selective compounds, broader adoption requires closing the translational gap between simulation predictions and in vivo outcomes. Key advancements will come from AI-refined force fields, integrative structural modeling of receptor complexes, and coupling MD with kinetic pharmacology. The ultimate goal is a predictive "digital pharmacology" platform. Within five years, cloud-based MD screening is expected to become standard, delivering safer, mechanism-based clinical candidates and paving the way for personalized neurotherapeutics.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: